The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MDNA | -19.17% | -73.92% | -23.56% | -33% |
| S&P | +14.49% | +91.09% | +13.83% | +173% |
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. It engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.
No news articles found for Medicenna Therapeutics.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.01M | -275.7% |
| Market Cap | $43.28M | -61.4% |
| Market Cap / Employee | $2.40M | 0.0% |
| Employees | 18 | 12.5% |
| Net Income | -$3.56M | -34.0% |
| EBITDA | -$3.97M | -34.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $14.99M | -42.4% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.08M | 0.0% |
| Short Term Debt | $0.04M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -42.71% | 32.4% |
| Return On Invested Capital | -148.34% | -7.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.56M | -48.6% |
| Operating Free Cash Flow | -$2.56M | -50.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 6.40 | 5.94 | 4.38 | 3.71 | -86.08% |
| Price to Tangible Book Value | 6.41 | 5.96 | 4.40 | 3.72 | -86.20% |
| Enterprise Value to EBITDA | -20.32 | -18.86 | -7.70 | -9.21 | -67.14% |
| Return on Equity | -122.3% | -150.3% | -100.5% | -69.2% | -33.91% |
| Total Debt | $0.13M | $0.12M | $0.12M | $0.12M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
